PATENT CLAIM ANALYSIS

Application Number: 16073934
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-05
Patent Classification: ["514", "403000"]

Abstract:
Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising a compound of formula I, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by aberrant complement system activity.

Claim (Index 32):
The method of  claim 31 , wherein the disease or condition characterized by aberrant complement system activity is an immunological disorder, a disease of the central nervous system, a neurodegenerative disease or neurological disease, a renal disease, or a cardiovascular disease.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 95.0
- Lexical Diversity: 1.59459
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15764071', '15247429', '14631828', '15905524', '15700550']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7922986735580707
- 35 USC 102 Novelty (BERT): 0.5511798455112089
- Combined Prediction Score: 0.7681867907533846
- Mean Citation Score: 398.325606
- Max Citation Score: 429.99738
- Similarity Product: 238.2286809188569

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test